Everything below concerns angiogenesis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-05. Numbers and descriptions here follow the published literature rather than marketing material.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
==== Market inclusion ==== Middlemen often extract exorbitant rents from farmers when purchasing their harvest or livestock for several reasons. First, smallholders in remote areas may be unaware of fair market prices. As a result, middlemen (who typically have better information about market conditions and prices) accrue significant market power and profits. A study conducted in the central highlands of Peru found that farmers who received market price information via mobile phone SMS increased their sales prices by 13-14% relative to farmers without access to the information. Second, smallholders produce tiny harvests compared to large producers, so they lack bargaining power with middlemen. If smallholders can aggregate or form a cooperative to sell their products together, they have more leverage. Online platforms and mobile phones can facilitate aggregation, such as Digital Green's Loop app. Third, connecting producers with final consumers can eliminate intermediaries' monopsony power, thereby raising producer profits. As mentioned above in the efficiency section, e-commerce or other market linkage platforms can connect a small farmer directly to consumers around the world.
=== Proteasomal ligases === While Ubp6 and UCH37 can remodel the ubiquitin code on a substrate by removing Ubiquitins, Ubiquitin ligases can also associate with the proteasome and attach ubiquitins. For the 26S, this includes Hul5 in yeast (or UBE3C in humans) and UBE3A/E6AP in humans. Hul5 was first identified in yeast as a 26S associated ligase along with Ubp6 and they were proposed to remodel ubiquitin chains at the proteasome. Biochemical studies show that Hul5 can attach additional ubiquitins onto a ubiquitinated substrate effectively acting as an Ubiquitin ligase. Hul5 has been proposed to bind Rpn2 in yeast, however this interaction has not been shown structurally. Further work needs to be done to understand how Hul5 works and what substrates are processed by Hul5. UBE3A/E6AP binds the C-terminus of Rpn10 in mammals. NMR has shown that a previously described disordered region of Rpn10 becomes order upon binding E6AP forming a tight interaction in the low nanomolar range.
==== Noncanonical pathways ==== The noncanonical planar cell polarity (PCP) pathway does not involve β-catenin. It does not use LRP-5/6 as its co-receptor and is thought to use NRH1, Ryk, PTK7 or ROR2. The PCP pathway is activated via the binding of Wnt to Fz and its co-receptor. The receptor then recruits Dsh, which uses its PDZ and DIX domains to form a complex with Dishevelled-associated activator of morphogenesis 1 (DAAM1). Daam1 then activates the small G-protein Rho through a guanine exchange factor. Rho activates Rho-associated kinase (ROCK), which is one of the major regulators of the cytoskeleton. Dsh also forms a complex with rac1 and mediates profilin binding to actin. Rac1 activates JNK and can also lead to actin polymerization. Profilin binding to actin can result in restructuring of the cytoskeleton and gastrulation.
During the Tet Offensive, which swept across South Vietnam in January/February 1968, the 3rd Brigade was en route to Chu Lai within 24 hours of receiving its orders. The 3rd Brigade performed combat duties in the Huế – Phu Bai area of the I Corps sector. Later the brigade moved south to Saigon, and fought in the Mekong Delta, the Iron Triangle and along the Cambodian border, serving nearly 22 months. While the 3rd Brigade was deployed, the division created a provisional 4th Brigade, consisting of 4th Battalion, 325th Infantry; 3d Battalion, 504th Infantry; and 3d Battalion, 505th Infantry. An additional unit, the 3d Battalion, 320th Artillery, was activated under Division Artillery to support the 4th Brigade. The units assigned and attached to the 3d Brigade of the 82nd Airborne Division were as follows:
The initial effects of exposure were coughing, severe eye irritation, a feeling of suffocation, burning in the respiratory tract, blepharospasm, breathlessness, stomach pains, and vomiting. People alerted by these symptoms fled from the plant. Those who ran inhaled more than those in vehicles. Owing to their height, children and other residents of shorter stature inhaled higher concentrations, as methyl isocyanate gas is approximately twice as dense as air and in an open environment has a tendency to fall toward the ground. Thousands of people had died by the following morning. Primary causes of deaths were choking, reflexogenic circulatory collapse, and pulmonary oedema. Findings during autopsies revealed changes not only in the lungs but also cerebral oedema, tubular necrosis of the kidneys, fatty degeneration of the liver, and necrotising enteritis. The individuals who did not die suffered from cancer, blindness, loss of livelihood, and financial strain.
Sources: en.wikipedia.org
Drug development is the process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery. It includes preclinical research on microorganisms and animals, filing for regulatory status, such as via the United States Food and Drug Administration for an investigational new drug to initiate clinical trials on humans, and may include the step of obtaining regulatory approval with a new drug application to market the drug. The entire process—from concept through preclinical testing in the laboratory to clinical trial development, including Phase I–III trials—to approved vaccine or drug typically takes more than a decade.
== P == PAS – Positron annihilation spectroscopy Photoacoustic spectroscopy PAT or PACT – Photoacoustic tomography or photoacoustic computed tomography PAX – Photoemission of adsorbed xenon PC or PCS – Photocurrent spectroscopy Phase contrast microscopy PhD – Photoelectron diffraction PD – Photodesorption PDEIS – Potentiodynamic electrochemical impedance spectroscopy PDS – Photothermal deflection spectroscopy PED – Photoelectron diffraction PEELS – parallel electron energy loss spectroscopy PEEM – Photoemission electron microscopy (or photoelectron emission microscopy) PES – Photoelectron spectroscopy PINEM – photon-induced near-field electron microscopy PIGE – Particle (or proton) induced gamma-ray spectroscopy, see nuclear reaction analysis PIXE – Particle (or proton) induced X-ray spectroscopy PL – Photoluminescence Porosimetry Powder diffraction PTMS – Photothermal microspectroscopy PTS – Photothermal spectroscopy
It has been estimated that only 10.33% of all municipal solid waste (MSW), which makes up to 30.3% of the total waste, is recycled into new products globally. However, depending on the level of packaging and the materials that are being used during their manufacturing, the end-of-life of a package may differ completely. Despite the fact that a recycling process is usually the desired path, lots of complications may lead to less sustainable destines.
Although sometimes applied to other cultures and religions, caste is a fundamental social institution of India, most fully developed among Hindus. All Hindus fall broadly into four castes, or varnas: Brahmin, or priests, at the top; below them Kshatriya, or warriors; further below, Vaishya, or merchants and farmers; and at the bottom, Shudra, or the service class. Outside the caste system, and of traditional Hinduism, lie people formerly called "outcastes" or "untouchables," and now scheduled caste (a term used in India's constitution) or Dalit, a later self-description of pride, meaning "broken" or "downtrodden". Each caste is further divided into sub-castes, or jātis, many of which are tied to occupations. However, the custom of endogamy, or marrying within one's subcaste, makes caste a hereditary label rather than one of occupational choice and has entrenched the caste system. The Constituent Assembly of India abolished untouchability in 1947, the Republic of India did more formally in 1950, and India has since enacted other anti-discrimination laws and social welfare initiatives related to caste. Still, caste-based inequality, discrimination, segregation, and violence persist. Multi-generational patrilineal joint families have been the norm in India, though nuclear families are becoming common in urban areas. A very large majority of Indians have their marriages arranged by their parents or family elders. Marriage is thought to be for life; and the divorce rate is extremely low, less than one in a thousand.
Later in September Roche announced its intention to acquire Tusk Therapeutics for up to €655 million ($759 million) expanding Roche's oncology pipeline. Tusk announced that the anti-CD38 antibody it is developing will be spun off to form a new company, Black Belt Therapeutics. In late November, the company announced that Genentech would acquire Jecure Therapeutics, gaining access to Jecure's portfolio of NLRP3 inhibitors developed to fight inflammatory diseases like non-alcoholic steatohepatitis and liver fibrosis. In February 2019, the business announced it would acquire gene therapy company, Spark Therapeutics, for US$4.3 billion ($114.50 per share) adding Spark's gene therapy portfolio to its previous acquired assets. Spark has an already approved treatment for Leber's congenital amaurosis, Luxturna – priced at US$850,000 per patient. The offer to acquire Spark Therapeutics was extended to May 2019 after Roche was unable to garner majority support from Spark shareholders. A second gene therapy-related action came in December with the US$1.15 billion acquisition of non-United States rights to an investigational duchenne muscular dystrophy gene therapy developed by Sarepta Therapeutics. In November, Roche acquired Promedior and its lead treatment – PRM-151 – for the treatment of idiopathic pulmonary fibrosis, for $390 million upfront and another $1 billion in milestone payments.
Sources: en.wikipedia.org
=== Other common diseases === EpiVacCorona, a peptide-based vaccine against COVID-19. IC41 is a peptide vaccine candidate against the Hepatitis C virus. It consists of five synthetic peptides along with the synthetic adjuvant called poly-l-arginine. Multimeric-001 is the most efficient peptide vaccine candidate against influenza. It contains B- and T-cell epitopes from Hemagglutinin. Matrix I and nucleoprotein are combined into a single recombinantly-expressed polypeptide. Alzheimer peptide vaccines: CAD106, UB311, Lu, AF20513, ABvac40, ACI-35, AADvac-1.
== Principle of the method == ZooMS identifies species based on differences in the amino acid composition of the collagen protein. The amino acid sequence of a species' collagen protein is determined by its DNA and as a result like DNA, the amino acid sequence reflects a species' evolutionary history. The greater the evolutionary distance between two species, the more different their collagen proteins will be. ZooMS typically can identify a sample up to genus level, though in some cases the identification can be more or less specific. A good understanding of the archaeological context of the sample can be used to further refine the resolution of the species identification.
== Signs and symptoms == The various types of VWD present with varying degrees of bleeding tendency, usually in the form of easy bruising, nosebleeds, and bleeding gums. Women may experience heavy menstrual periods and blood loss during childbirth. Symptoms of VWD vary depending on age, sex, and VWD type. In children, bruising and nosebleeds are common symptoms. In adults, easy bruising, heavy menstrual bleeding, and bleeding from minor wounds are more common. Sixty to eighty percent of people with VWD have excessive bleeding after surgery or dental extractions. Gastrointestinal bleeding from dilated blood vessels lining the gut (angiodysplasia) can result in severe, lifethreatening gastrointestinal bleeding. This most commonly occurs in seniors with type 2 or 3 VWD. Von Willebrand factor levels normally increase with age, so disease severity often decreases with older age. In women with VWD, 80% have heavy menstrual bleeding with 20% requiring removal of the uterus (hysterectomy). Due to its association with heavy menstrual bleeding, VWD is more commonly diagnosed in women. Women with VWD may also experience heavy bleeding after delivery (postpartum bleeding). Severe internal bleeding and bleeding into joints are rare in those with VWD, but they are more common in those with the more severe type 3 disease. Bleeding in the brain or spinal cord is exceedingly rare in all 3 types of VWD.
== Composition == The substance is primarily composed of polysaccharides, including galactose, rhamnose, and α-glucuronic acid. It also contains dietary fiber, carbohydrates, proteins, and small amounts of vitamins. Despite marketing claims, peach gum does not contain collagen, which is exclusive to animal tissues.
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
Human data are limited. Most evidence comes from animal experiments and from small or uncontrolled reports. The absence of large trials means clinical effects and safety are not firmly established.